Formosa Pharmaceuticals and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the treatment of Acute Dry Eye Disease in the U.S.
Formosa Pharmaceuticals and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the treatment of Acute Dry Eye Disease in the U.S. TAIPEI – August 7, 2023 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. (“Eyenovia”, NASDAQ: EYEN), whereby the …